A Randomised, Double-blind, Double Dummy, Active Controlled, Parallel Group, Forced Titration Study to Compare the Fixed-dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 25mg (T80/HCTZ25) Versus Telmisartan 80mg (T80) Monotherapy as First Line Therapy in Patients With Grade 2 or Grade 3 Hypertension (SBP>=160 mmHg and DBP>=100 mmHg).

Trial Profile

A Randomised, Double-blind, Double Dummy, Active Controlled, Parallel Group, Forced Titration Study to Compare the Fixed-dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 25mg (T80/HCTZ25) Versus Telmisartan 80mg (T80) Monotherapy as First Line Therapy in Patients With Grade 2 or Grade 3 Hypertension (SBP>=160 mmHg and DBP>=100 mmHg).

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2013

At a glance

  • Drugs Telmisartan/hydrochlorothiazide (Primary) ; Telmisartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 14 Nov 2012 Results, including prespecified subgroup analyses, presented at the 2012 Annual Meeting of the North American Association for the Study of Obesity.
    • 18 Jun 2012 Results published in Clinical Therapeutics.
    • 14 Jun 2010 Actual patient number (894) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top